News & Events

College Hill Wins Global PR Account with NASDAQ-listed Astex Pharmaceuticals

College Hill Wins Global PR Account with NASDAQ-listed Astex Pharmaceuticals

27 January 2012, London, Manchester, Munich, Sydney, Boston, Atlanta: The Life Sciences team of international business communications consultancy, College Hill has announced that it has won the global mandate to support Astex Pharmaceuticals, Inc. (NASDAQ: ASTX) in its corporate communications.

The Astex win follows College Hill’s successful support of Cambridge-based private biotechnology company Astex Therapeutics Limited in its cross-border acquisition by US Company SuperGen, Inc. in July 2011. Astex Pharmaceuticals, which was renamed and rebranded post the merger of the two entities, is focused primarily on developing cancer therapies, and has a drug on the market, a pipeline of promising drug candidates, and a strong R&D base with novel technologies and platforms in the areas of fragment-based drug design and epigenetics. It has bases in Dublin, California and Cambridge, England.

College Hill’s remit is to provide media outreach, financial and corporate communications support to the post-transaction enlarged group. The Astex team is led by College Hill Life Sciences’ head of financial communications, Melanie Toyne Sewell, supported by Daniel Gooch in London and Rebecca Skye Dietrich in Boston with additional strategic counsel from Sue Charles. It reports into California-based Tim Enns, senior vice president of Corporate Communications and Marketing at Astex.

Commenting on the win, Melanie Toyne Sewell said: “We are delighted to have been appointed to support Astex on a global basis. The win underlines our ability to serve global accounts in an integrated way, drawing together teams across our offices.” She continued: “The win also reflects the quality of our work during the acquisition and integration; the coverage achieved was widespread across the US and Europe, and supportive of the deal. We very much look forward to working with Tim and the management team to continue that success.”

The new account, which kicked off in November 2011 and will roll out over 2012, follows other recent international wins including AU$1,850m+ market cap ASX-listed Mesoblast, a global leader in the emerging field of regenerative medicine and stem cell therapies. College Hill picked up the Mesoblast account mid-2011 and supports its European financial and healthcare communications as well as design and copywriting for corporate materials.

In 2011 College Hill Life Sciences extended its reach in the US with the appointment of a senior consultant heading business development and has announced that during 2012 it will be formalising its presence in Australia with teams based in both Sydney and Melbourne. To date, the team has picked up briefs from over 10 Australian-based clients.

Commenting on its international success and global ambitions, Sue Charles, Managing Partner of the Life Sciences practice said: “Our industry and client base is very global, with typical programmes needing strategic input based on global knowledge and experience, as well as the ability to execute on outreach in multiple territories. We have built a team that has this perspective and capability, and it has enabled us to pick up business and expand, even in today’s tough economic climate.”

For further information:
Sue Charles, Managing Partner
UK: +44 (0)20 7457 2020/ +44 (0)7968 726 585
sue.charles [at]

back to news